All IndicationsApprovedApprovedApprovedPhase 3Phase 3Phase 3Phase 3Phase 2
Polycythemia Vera
5
Companies
8
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
VERA
Vera Therapeutics
rusfertide
TAK
Takeda
rusfertide
PRTX
Protagonist Therapeutics
rusfertide
INCY
Incyte Corporation
ruxolitinib tablets
PRTX
Protagonist Therapeutics, Inc.
Open-label rusfertide
PRTX
Protagonist Therapeutics, Inc.
Placebo
INCY
Incyte Corporation
Hydroxyurea (HU)
TXMD
TherapeuticsMD, Inc.
PTG-300
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VERA Vera Therapeutics | rusfertide | Approved | — | — | — |
| TAK Takeda | rusfertide | Approved | — | — | — |
| PRTX Protagonist Therapeutics | rusfertide | Approved | — | — | — |
| INCY Incyte Corporation | ruxolitinib tablets | Phase 3 | — | — | — |
| PRTX Protagonist Therapeutics, Inc. | Open-label rusfertide | Phase 3 | — | — | — |
| PRTX Protagonist Therapeutics, Inc. | Placebo | Phase 3 | — | — | — |
| INCY Incyte Corporation | Hydroxyurea (HU) | Phase 3 | — | — | — |
| TXMD TherapeuticsMD, Inc. | PTG-300 | Phase 2 | — | — | — |
Development Stage Distribution
Approved
3
Phase 3
4
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.